Patents by Inventor Wojtek Auerbach

Wojtek Auerbach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200002730
    Abstract: Compositions and methods are provided for creating and promoting biallelic targeted modifications to genomes within cells and for producing non-human animals comprising the modified genomes. Also provided are compositions and methods for modifying a genome within a cell that is heterozygous for an allele to become homozygous for that allele. The methods make use of Cas proteins and two or more guide RNAs that target different locations within the same genomic target locus. Also provided are methods of identifying cells with modified genomes.
    Type: Application
    Filed: September 16, 2019
    Publication date: January 2, 2020
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: David Frendewey, Ka-Man Venus Lai, Wojtek Auerbach, Gustavo Droguett, Anthony Gagliardi, David M. Valenzuela, Vera Voronina, Lynn Macdonald, Andrew J. Murphy, George D. Yancopoulos
  • Publication number: 20190382730
    Abstract: Methods and compositions are provided for generating or maintaining human iPS cells in culture. Methods include the use of a low osmolality medium to make human iPS cells, or use of a low osmolality medium to maintain human iPS cells. Methods for making targeted genetic modification to human iPS cells cultured in low osmolality medium are also included. Compositions include human iPS cells cultured and maintained using the low osmolality medium defined herein.
    Type: Application
    Filed: August 5, 2019
    Publication date: December 19, 2019
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Junko Kuno, Wojtek Auerbach, David M. Valenzuela
  • Patent number: 10457960
    Abstract: Compositions and methods are provided for creating and promoting biallelic targeted modifications to genomes within cells and for producing non-human animals comprising the modified genomes. Also provided are compositions and methods for modifying a genome within a cell that is heterozygous for an allele to become homozygous for that allele. The methods make use of Cas proteins and two or more guide RNAs that target different locations within the same genomic target locus. Also provided are methods of identifying cells with modified genomes.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: October 29, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David Frendewey, Ka-Man Venus Lai, Wojtek Auerbach, Gustavo Droguett, Anthony Gagliardi, David M. Valenzuela, Vera Voronina, Lynn Macdonald, Andrew J. Murphy, George D. Yancopoulos
  • Publication number: 20190323032
    Abstract: Compositions and methods are provided for modifying a rat genomic locus of interest using a large targeting vector (LTVEC) comprising various endogenous or exogenous nucleic acid sequences as described herein. Compositions and methods for generating a genetically modified rat comprising one or more targeted genetic modifications in their germline are also provided. Compositions and methods are provided which comprise a genetically modified rat or rat cell comprising a targeted genetic modification in the rat interleukin-2 receptor gamma locus, the rat ApoE locus, the rat Rag2 locus, the rat Rag1 locus and/or the rat Rag2/Rag1 locus. The various methods and compositions provided herein allows for these modified loci to be transmitted through the germline.
    Type: Application
    Filed: June 25, 2019
    Publication date: October 24, 2019
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Jeffrey D. Lee, Alexander O. Mujica, Wojtek Auerbach, Ka-Man Venus Lai, David M. Valenzuela, George D. Yancopoulos
  • Publication number: 20190316149
    Abstract: Compositions and methods are provided for making rat pluripotent and totipotent cells, including rat embryonic stem (ES) cells. Compositions and methods for improving efficiency or frequency of germline transmission of genetic modifications in rats are provided. Such methods and compositions comprise an in vitro culture comprising a feeder cell layer and a population of rat ES cells or a rat ES cell line, wherein the in vitro culture conditions maintain pluripotency of the ES cell and comprises a media having mouse leukemia inhibitory factor (LIF) or an active variant or fragment thereof. Various methods of establishing such rat ES cell lines are further provided. Methods of selecting genetically modified rat ES cells are also provided, along with various methods to generate a transgenic rat from the genetically modified rat ES cells provided herein. Various kits and articles of manufacture are further provided.
    Type: Application
    Filed: May 2, 2019
    Publication date: October 17, 2019
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Jeffrey D. Lee, Wojtek Auerbach, David Heslin, David Frendewey, Ka-Man Venus Lai, David M. Valenzuela
  • Patent number: 10428310
    Abstract: Methods and compositions are provided for generating or maintaining human iPS cells in culture. Methods include the use of a low osmolality medium to make human iPS cells, or use of a low osmolality medium to maintain human iPS cells. Methods for making targeted genetic modification to human iPS cells cultured in low osmolality medium are also included. Compositions include human iPS cells cultured and maintained using the low osmolality medium defined herein.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: October 1, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Junko Kuno, Wojtek Auerbach, David M. Valenzuela
  • Patent number: 10385359
    Abstract: Compositions and methods are provided for modifying a rat genomic locus of interest using a large targeting vector (LTVEC) comprising various endogenous or exogenous nucleic acid sequences as described herein. Compositions and methods for generating a genetically modified rat comprising one or more targeted genetic modifications in their germline are also provided. Compositions and methods are provided which comprise a genetically modified rat or rat cell comprising a targeted genetic modification in the rat interleukin-2 receptor gamma locus, the rat ApoE locus, the rat Rag2 locus, the rat Rag1 locus and/or the rat Rag2/Rag1 locus. The various methods and compositions provided herein allows for these modified loci to be transmitted through the germline.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: August 20, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jeffrey D. Lee, Alexander O. Mujica, Wojtek Auerbach, Ka-Man Venus Lai, David M. Valenzuela, George D. Yancopoulos
  • Publication number: 20190225992
    Abstract: Methods and compositions are provided for modifying one or more target loci in a cell. Such methods comprise providing a cell comprising a first polynucleotide encoding a first selection marker operably linked to a first promoter active in the cell, wherein the first polynucleotide further comprises a first recognition site for a first nuclease agent. A first nuclease agent is introduced into a cell, wherein the first nuclease agent induces a nick or double-strand break at the first recognition site. Further introduced into the cell is a first targeting vector comprising a first insert polynucleotide flanked by a first and a second homology arm that correspond to a first and a second target site located in sufficient proximity to the first recognition site. At least one cell is then identified comprising in its genome the first insert polynucleotide integrated at the target locus.
    Type: Application
    Filed: March 29, 2019
    Publication date: July 25, 2019
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Wojtek Auerbach, David Frendewey, Gustavo Droguett, Anthony Gagliardi, Junko Kuno, David M. Valenzuela
  • Patent number: 10329582
    Abstract: Compositions and methods are provided for making rat pluripotent and totipotent cells, including rat embryonic stem (ES) cells. Compositions and methods for improving efficiency or frequency of germline transmission of genetic modifications in rats are provided. Such methods and compositions comprise an in vitro culture comprising a feeder cell layer and a population of rat ES cells or a rat ES cell line, wherein the in vitro culture conditions maintain pluripotency of the ES cell and comprises a media having mouse leukemia inhibitory factor (LIF) or an active variant or fragment thereof. Various methods of establishing such rat ES cell lines are further provided. Methods of selecting genetically modified rat ES cells are also provided, along with various methods to generate a transgenic rat from the genetically modified rat ES cells provided herein. Various kits and articles of manufacture are further provided.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: June 25, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jeffrey D. Lee, Wojtek Auerbach, David Heslin, David Frendewey, Ka-Man Venus Lai, David M. Valenzuela
  • Patent number: 10301646
    Abstract: Compositions and methods are provided for making one or more targeted genetic modifications at a target genomic locus by employing homologous recombination facilitated by single or double-strand break at or near the target genomic locus. Compositions and methods for promoting efficiency of homologous recombination between an LTVEC and a target genomic locus in prokaryotic or eukaryotic cells using engineered nucleases are also provided.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: May 28, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David Frendewey, Wojtek Auerbach, David M. Valenzuela, George D. Yancopoulos, Ka-Man Venus Lai
  • Patent number: 10294494
    Abstract: Methods and compositions are provided for modifying one or more target loci in a cell. Such methods comprise providing a cell comprising a first polynucleotide encoding a first selection marker operably linked to a first promoter active in the cell, wherein the first polynucleotide further comprises a first recognition site for a first nuclease agent. A first nuclease agent is introduced into a cell, wherein the first nuclease agent induces a nick or double-strand break at the first recognition site. Further introduced into the cell is a first targeting vector comprising a first insert polynucleotide flanked by a first and a second homology arm that correspond to a first and a second target site located in sufficient proximity to the first recognition site. At least one cell is then identified comprising in its genome the first insert polynucleotide integrated at the target locus.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: May 21, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Wojtek Auerbach, David Frendewey, Gustavo Droguett, Anthony Gagliardi, Junko Kuno, David M. Valenzuela
  • Publication number: 20190112619
    Abstract: Compositions and methods are provided for modifying a genomic locus of interest in a eukaryotic cell, a mammalian cell, a human cell or a non-human mammalian cell using a large targeting vector (LTVEC) comprising various endogenous or exogenous nucleic acid sequences as described herein. Further methods combine the use of the LTVEC with a CRISPR/Cas system. Compositions and methods for generating a genetically modified non-human animal comprising one or more targeted genetic modifications in their germline are also provided.
    Type: Application
    Filed: December 18, 2018
    Publication date: April 18, 2019
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: David Frendewey, Wojtek Auerbach, Ka-Man Venus Lai, David M. Valenzuela, George D. Yancopoulos
  • Patent number: 10208317
    Abstract: Compositions and methods are provided for modifying a genomic locus of interest in a eukaryotic cell, a mammalian cell, a human cell or a non-human mammalian cell using a large targeting vector (LTVEC) comprising various endogenous or exogenous nucleic acid sequences as described herein. Further methods combine the use of the LTVEC with a CRISPR/Cas system. Compositions and methods for generating a genetically modified non-human animal comprising one or more targeted genetic modifications in their germline are also provided.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: February 19, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David Frendewey, Wojtek Auerbach, Ka-Man Venus Lai, David M. Valenzuela, George D. Yancopoulos
  • Patent number: 10106820
    Abstract: Methods and compositions are provided for modifying one or more target loci in a cell. Such methods comprise providing a cell comprising a first polynucleotide encoding a first selection marker operably linked to a first promoter active in the cell, wherein the first polynucleotide further comprises a first recognition site for a first nuclease agent. A first nuclease agent is introduced into a cell, wherein the first nuclease agent induces a nick or double-strand break at the first recognition site. Further introduced into the cell is a first targeting vector comprising a first insert polynucleotide flanked by a first and a second homology arm that correspond to a first and a second target site located in sufficient proximity to the first recognition site. At least one cell is then identified comprising in its genome the first insert polynucleotide integrated at the target locus.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: October 23, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Wojtek Auerbach, David Frendewey, Gustavo Droguett, Anthony Gagliardi, Junko Kuno, David M. Valenzuela
  • Publication number: 20180251784
    Abstract: Methods and compositions are provided for generating targeted genetic modifications on the Y chromosome or a challenging target locus. Compositions include an in vitro culture comprising an XY pluripotent and/or totipotent animal cell (i.e., XY ES cells or XY iPS cells) having a modification that decreases the level and/or activity of an Sry protein; and, culturing these cells in a medium that promotes development of XY F0 fertile females. Such compositions find use in various methods for making a fertile female XY non-human mammal in an F0 generation.
    Type: Application
    Filed: February 22, 2018
    Publication date: September 6, 2018
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: David Frendewey, Gustavo Droguett, Anthony Gagliardi, Junko Kuno, Wojtek Auerbach, David M. Valenzuela
  • Patent number: 10039269
    Abstract: Methods of generating modified embryos and mammals by introduction of donor cells into an early stage embryo are provided, such that the resulting embryo and animal generated therefrom has a significant contribution to all tissues from the donor cells and is capable of transmitting the donor cell DNA.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: August 7, 2018
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: William Poueymirou, Thomas M. DeChiara, Wojtek Auerbach, David Frendewey, David M. Valenzuela
  • Patent number: 9902971
    Abstract: Methods and compositions are provided for generating targeted genetic modifications on the Y chromosome or a challenging target locus. Compositions include an in vitro culture comprising an XY pluripotent and/or totipotent animal cell (i.e., XY ES cells or XY iPS cells) having a modification that decreases the level and/or activity of an Sry protein; and, culturing these cells in a medium that promotes development of XY F0 fertile females. Such compositions find use in various methods for making a fertile female XY non-human mammal in an F0 generation.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: February 27, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David Frendewey, Gustavo Droguett, Anthony Gagliardi, Junko Kuno, Wojtek Auerbach, David M. Valenzuela
  • Publication number: 20180037910
    Abstract: Compositions and methods are provided for making one or more targeted genetic modifications at a target genomic locus by employing homologous recombination facilitated by single or double-strand break at or near the target genomic locus. Compositions and methods for promoting efficiency of homologous recombination between an LTVEC and a target genomic locus in prokaryotic or eukaryotic cells using engineered nucleases are also provided.
    Type: Application
    Filed: October 24, 2017
    Publication date: February 8, 2018
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: David Frendewey, Wojtek Auerbach, David M. Valenzuela, George D. Yancopoulos, Ka-Man Venus Lai
  • Patent number: 9885058
    Abstract: Methods and compositions are described for making phenotypically female fertile animals from XY donor cells and suitable host embryos. Culture media and methods are provided for maintaining XY donor cells in culture that after introduction into a host embryo and gestation in a suitable host will result in fertile XY female animals. Methods and compositions are described for making fertile female animals in an F0 generation from a donor XY cell and a host embryo, as are methods for making F1 progeny that are homozygous for a modification from a heterozygous F0 fertile male and a heterozygous F0 fertile female sibling.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: February 6, 2018
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Wojtek Auerbach, Thomas DeChiara, William Poueymirou, David Frendewey, David Valenzuela
  • Patent number: 9834786
    Abstract: Compositions and methods are provided for making one or more targeted genetic modifications at a target genomic locus by employing homologous recombination facilitated by single or double-strand break at or near the target genomic locus. Compositions and methods for promoting efficiency of homologous recombination between an LTVEC and a target genomic locus in prokaryotic or eukaryotic cells using engineered nucleases are also provided.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: December 5, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David Frendewey, Wojtek Auerbach, David M. Valenzuela, George D. Yancopoulos, Ka-Man Venus Lai